Application of Nanoparticles for Immunotherapy of Allergic Rhinitis

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2024 Nov 25

PMID 39583318

Authors

Kaiqiang Li

Jing Jin

Yimin Yang

Xuling Luo

Yaling Wang

Aibo Xu

Ke Hao

Zhen Wang

Affiliations

Soon will be listed here.

Abstract

Allergen Immunotherapy (AIT) is the only etiological therapeutic method available for allergic rhinitis (AR). Currently, several options for AIT in the market, such as subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), have different routes of administration. These traditional methods have achieved encouraging outcomes in clinic. However, the side effects associated with these methods have raised the need for innovative approaches for AIT that improve safety, shorten the course of treatment and increase local drug concentration. Nanoparticles (NPs) are particles ranging in size from 1 to 100 nm, which have been hired as potential adjuvants for AIT. NPs can be employed as agents for modulating immune responses in AR or/and carriers for loading proteins, peptides or DNA molecules. This review focuses on different kinds of nanoparticle delivery systems, including chitosan nanoparticles, exosomes, metal nanoparticles, and viral nanoparticles. We summarized the advantages and limitations of NPs for the treatment of allergic rhinitis. Overall, NPs are expected to be a therapeutic option for AR, which requires more in-depth studies and long-term therapeutic validation.

References

Zhang Y, Lan F, Zhang L . Update on pathomechanisms and treatments in allergic rhinitis. Allergy. 2022; 77(11):3309-3319. DOI: 10.1111/all.15454. View

Roach K, Stefaniak A, Roberts J . Metal nanomaterials: Immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease. J Immunotoxicol. 2019; 16(1):87-124. PMC: 6649684. DOI: 10.1080/1547691X.2019.1605553. View

Garcia-Fernandez A, Sancenon F, Martinez-Manez R . Mesoporous silica nanoparticles for pulmonary drug delivery. Adv Drug Deliv Rev. 2021; 177:113953. DOI: 10.1016/j.addr.2021.113953. View

Zhu H, Tang K, Chen G, Liu Z . Biomarkers in oral immunotherapy. J Zhejiang Univ Sci B. 2022; 23(9):705-731. PMC: 9483607. DOI: 10.1631/jzus.B2200047. View

Ishii M, Koyama A, Iseki H, Narumi H, Yokoyama N, Kojima N . Anti-allergic potential of oligomannose-coated liposome-entrapped Cry j 1 as immunotherapy for Japanese cedar pollinosis in mice. Int Immunopharmacol. 2010; 10(9):1041-6. DOI: 10.1016/j.intimp.2010.06.003. View

Xu L, Wang X, Wang W, Sun M, Choi W, Kim J . Enantiomer-dependent immunological response to chiral nanoparticles. Nature. 2022; 601(7893):366-373. DOI: 10.1038/s41586-021-04243-2. View

Ronzani C, Casset A, Pons F . Exposure to multi-walled carbon nanotubes results in aggravation of airway inflammation and remodeling and in increased production of epithelium-derived innate cytokines in a mouse model of asthma. Arch Toxicol. 2013; 88(2):489-99. DOI: 10.1007/s00204-013-1116-3. View

Kocholata M, Prusova M, Auer Malinska H, Maly J, Janouskova O . Comparison of two isolation methods of tobacco-derived extracellular vesicles, their characterization and uptake by plant and rat cells. Sci Rep. 2022; 12(1):19896. PMC: 9674704. DOI: 10.1038/s41598-022-23961-9. View

Dumortier H . When carbon nanotubes encounter the immune system: desirable and undesirable effects. Adv Drug Deliv Rev. 2013; 65(15):2120-6. DOI: 10.1016/j.addr.2013.09.005. View

10.

Ding M, Liang Q, Xu H, Li X, Zhang K, Wei Z . Smart Peptide Defense Web In Situ Connects for Continuous Interception of IgE against Allergic Rhinitis. ACS Appl Mater Interfaces. 2022; 14(26):29639-29649. DOI: 10.1021/acsami.2c07092. View

11.

Fanuel S, Tabesh S, Rajani H, Heidari S, Sadroddiny E, Kardar G . Decorating and loading ghosts with allergens for allergen immunotherapy. Hum Vaccin Immunother. 2017; 13(10):2428-2433. PMC: 5647983. DOI: 10.1080/21645515.2017.1365208. View

12.

Xia J, Miao Y, Wang X, Huang X, Dai J . Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine. Biomed Pharmacother. 2022; 152:113250. DOI: 10.1016/j.biopha.2022.113250. View

13.

Tasaniyananda N, Chaisri U, Tungtrongchitr A, Chaicumpa W, Sookrung N . Mouse Model of Cat Allergic Rhinitis and Intranasal Liposome-Adjuvanted Refined Fel d 1 Vaccine. PLoS One. 2016; 11(3):e0150463. PMC: 4783078. DOI: 10.1371/journal.pone.0150463. View

14.

Farjadian F, Moghoofei M, Mirkiani S, Ghasemi A, Rabiee N, Hadifar S . Bacterial components as naturally inspired nano-carriers for drug/gene delivery and immunization: Set the bugs to work?. Biotechnol Adv. 2018; 36(4):968-985. PMC: 5971145. DOI: 10.1016/j.biotechadv.2018.02.016. View

15.

Sun M, Yu X, Wang T, Bi S, Liu Y, Chen X . Nasal adaptive chitosan-based nano-vehicles for anti-allergic drug delivery. Int J Biol Macromol. 2019; 135:1182-1192. DOI: 10.1016/j.ijbiomac.2019.05.188. View

16.

Shershakova N, Baraboshkina E, Andreev S, Purgina D, Struchkova I, Kamyshnikov O . Anti-inflammatory effect of fullerene C60 in a mice model of atopic dermatitis. J Nanobiotechnology. 2016; 14:8. PMC: 4727272. DOI: 10.1186/s12951-016-0159-z. View

17.

Moten D, Kolchakova D, Todorov K, Mladenova T, Dzhambazov B . Design of an Epitope-Based Peptide Vaccine Against the Major Allergen Amb a 11 Using Immunoinformatic Approaches. Protein J. 2022; 41(2):315-326. PMC: 8972712. DOI: 10.1007/s10930-022-10050-z. View

18.

Sakamoto M, Asahina R, Kamishina H, Maeda S . Transcription of thymic stromal lymphopoietin via Toll-like receptor 2 in canine keratinocytes: a possible association of Staphylococcus spp. in the deterioration of allergic inflammation in canine atopic dermatitis. Vet Dermatol. 2016; 27(3):184-e46. DOI: 10.1111/vde.12301. View

19.

Pohlit H, Bellinghausen I, Schomer M, Heydenreich B, Saloga J, Frey H . Biodegradable pH-Sensitive Poly(ethylene glycol) Nanocarriers for Allergen Encapsulation and Controlled Release. Biomacromolecules. 2015; 16(10):3103-11. DOI: 10.1021/acs.biomac.5b00458. View

20.

Klimek L, Schmidt-Weber C, Kramer M, Skinner M, Heath M . Clinical use of adjuvants in allergen-immunotherapy. Expert Rev Clin Immunol. 2017; 13(6):599-610. DOI: 10.1080/1744666X.2017.1292133. View